Skip to main content
. 2023 Feb 8;15(4):1092. doi: 10.3390/cancers15041092

Figure 3.

Figure 3

Involvement of PAI-1 in tolerance to osimertinib in EGFR-mutated lung cancer via its association with EMT. (A,B) qRT-PCR analysis of mRNA expression of PAI-1 and EMT-related genes in (A) H1975 and (B) PC-9 cells. The mRNA expression was measured on days 4 and 8 after osimertinib treatment. Relative expression level of each gene is shown with standard error bars (n = 4); * p < 0.05 compared with cells exposed to vehicle controls (one-way ANOVA with Tukey’s test). (C,D) qRT-PCR analysis of the mRNA expression of PAI-1 and EMT markers in osimertinib-tolerant (C) H1975 and (D) PC-9 cells. These osimertinib-tolerant cells were treated with SK-216 combined with osimertinib, and the mRNA expression of these genes was evaluated 48 h after SK-216 and osimertinib administration. The relative expression level of each gene is shown with standard error bars (n = 4); * p < 0.05 compared with cells exposed to vehicle controls (Student’s t-test).